Potent and highly selective neurokinin antagonists.
Ward
P
P
Department of Medicinal Chemistry, Glaxo Group Research Ltd., Greenford, Middlesex, U.K.
Ewan
G B
GB
Jordan
C C
CC
Ireland
S J
SJ
Hagan
R M
RM
Brown
J R
JR
D000595:Amino Acid Sequence; D000818:Animals; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects / Q000502:physiology; D008969:Molecular Sequence Data; D015394:Molecular Structure; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D015288:Neurokinin A / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis / Q000494:pharmacology; D015287:Neurokinin B / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis / Q000494:pharmacology; D011487:Protein Conformation; D051381:Rats; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D018042:Receptors, Neurokinin-3; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000378:metabolism; D013329:Structure-Activity Relationship; D013373:Substance P / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis / Q000494:pharmacology
D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D018042:Receptors, Neurokinin-3; D017981:Receptors, Neurotransmitter; D013373:Substance P; D015288:Neurokinin A; D015287:Neurokinin B